Autoimmune hemolytic anemia natural history, complications and prognosis
Autoimmune hemolytic anemia Microchapters |
Differentiating Autoimmune hemolytic anemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Autoimmune hemolytic anemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Autoimmune hemolytic anemia natural history, complications and prognosis |
FDA on Autoimmune hemolytic anemia natural history, complications and prognosis |
CDC on Autoimmune hemolytic anemia natural history, complications and prognosis |
Autoimmune hemolytic anemia natural history, complications and prognosis in the news |
Blogs on Autoimmune hemolytic anemia natural history, complications and prognosis |
Directions to Hospitals Treating Autoimmune hemolytic anemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Natural History
Complications
- Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).[1]
- Severe anemia
Prognosis
AIHA in children generally has a good prognosis and is self-limiting. However, if it presents within the first two years of life or in the teenage years, the disease often follows a more chronic course, requiring long term immunosuppression, with serious developmental consequences.
References
- ↑ Zecca M, Nobili B, Ramenghi U; et al. (2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857–61. doi:10.1182/blood-2002-11-3547. PMID 12531800. Unknown parameter
|month=
ignored (help)